biOasis Enters Investor Relations Agreement With Brisco Capital Partners Corp.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 16, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) (the "Company") is pleased to announce that it has Brisco Capital Partners Corp. ("Brisco") to provide investor relations, subject to regulatory approval. Brisco will initiate and maintain contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the Company and its activities. Brisco takes a full service approach to investor relations and provides creative investor relations programs for Canadian public companies.

Brisco is a Calgary-based investor relations firm that has represented a number of companies over the past 13 years including: Centurion Energy International Inc.; Canadian Crude Income Trust; Anglo Potash Ltd.; Vero Energy Inc.; Kirkland Lake Gold; Antares Minerals Inc.; and Resverlogix Corp.

The agreement is effective immediately and may be terminated by either party with thirty day written notice. Brisco will receive a monthly fee of $6,000 and are granted 250,000 share purchase options, of which 125,000 are to Brisco and 125,000 to Graeme Dick, a partner of Brisco. The options are exercisable for thirteen months from grant date at $1.05 per share and each are subject to vesting over 12 months as follows: 31,250 three months after date of grant and 31,250 each, each three months thereafter. The options follow the guidelines as set out in the Company's stock option plan and as set by TSX Venture Policy. Both the consulting agreement and the options grant are subject to the approval of the TSX Venture Exchange.

Graeme Dick, Brisco partner stated, "biOasis is an extremely interesting company given its development of blood-brain barrier therapies designed to target central nervous system disorders and diseases." He continued, "The Research, Evaluation and Option agreement with Shire Human Genetic Therapies Inc. is clearly an affirmation of the Company's Transcend technology and we are excited to be working with Rob and his team."

ABOUT BIOASIS:

biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest, a blood test for the diagnosis of Alzheimer's disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.

ABOUT TRANSCEND:

biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood-brain barrier - Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood-brain barrier - Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic therapeutics. To address the unmet clinical need to transport drugs across the blood brain barrier biOasis intends to license Transcend to multiple corporate partners.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased or p97 as a Physician's Aid to Diagnose Alzheimer's, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Robin Hutchison, Chairman & CEO